Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab + Chemotherapy + Radiotherapy as Neoadjuvant Treatment for Resectable ESCC
NCT07403435Phase 2Not yet recruiting
- Start
- Feb 2026
- Primary completion
- May 2027
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of serplulimab in Esophageal Squamous Cell Carcinoma (ESCC). Primary endpoint: Pathological Complete Response. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07403435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07403435.